The Difference is in the Data
MMS is the data-focused CRO driving pharmaceutical and biotech innovation with unparalleled regulatory expertise and technological innovation. Our experts across four continents are available to support your programs 24 hours a day with an industry-leading Sponsor satisfaction rating.
Full Service Biometrics
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
Regulatory Submissions
From the Investigational New Drug (IND) application stage through New Drug Applications (NDA), our deep expertise ensures that your drug development process is efficient, compliant, and strategically aligned with standards set by global health authorities.
Safety & Risk Management
Comprehensive pharmacovigilance, safety and risk management from Phase 1 through post approval, tailored to your specific needs.
Therapeutic Expertise
From industry-firsts to well-researched indications, MMS brings specialized knowledge in rare diseases, psychedelics, oncology and radiopharmaceuticals, central nervous system (CNS) disorders, and many others.
Functional Service Provider (FSP)
A flexible and scalable FSP model, providing the right level of oversight, scale, and governance to achieve your long- and short-term strategic goals.
What Differentiates MMS From Other CROs?
Responsive
MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.
Adaptable
MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.
Focused
MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.
This team never stopped working towards our deadline, and from day one, we were impressed with the efficient and smart decisions brought forth by MMS to bring this drug to market.
The choice in collaborating with MMS to meet this milestone… was simple, given their deep scientific knowledge and strategic resource models.
I cannot thank the MMS Team for the outstanding support you’re providing to ensure these are prepared for submission. I am continuously impressed with the MMS team and truly value the partnership.
AI and Technology
Sponsors can rest assured knowing that MMS will bring new levels of innovation and technology to our processes and deliverables.
in Michigan
Colleagues
Globally
Applications in the
Last 5 Years
trust
Upcoming Events
MMS Insights
webinar
December 4th, 2025
Writing with Quality Control in Mind: A Cross-functional Approach
perspectives
November 4th, 2025
4 Key Takeaways from the EMA - Health Canada Joint Review Process and Evaluation of Its Efficiency
perspectives
October 28th, 2025
New Updates on Clinical Trial Transparency and Regulatory Requirements: A Comprehensive Overview
webinar
October 21st, 2025
A Practical Guide to Expedited Regulatory Pathways
perspectives
October 21st, 2025
Shaping Clinical Development Through Writing: Francesca’s Journey at MMS
news
October 16th, 2025
MMS Named Finalist in the Fierce Life Sciences Innovation Awards for KerusCloud® Clinical Trial Simulation Platform
perspectives
October 14th, 2025
CRO Partnerships and Biotech Agility: How Smaller Sponsors Gain Speed in Clinical Development
perspectives
October 7th, 2025
From Academia to Building Medical Writing Partnerships: Jessica Murdock’s MMS Story
news
October 2nd, 2025
MMS Announces Its Role in Supporting Gates Ventures and the GNPC to Deliver One of the World's Largest Proteomic Datasets for Neurodegenerative Diseases
perspectives
September 30th, 2025
Ready by Design: Endpoints, Feasibility, and Scenario Testing
webinar
September 25th, 2025
The Psychedelic Inflection Point: What Sponsors Need to Know Now
news
September 24th, 2025
MMS Named Finalist in Citeline’s 2025 Scrip Awards for Best Contract Research Organization (CRO) – Specialist Providers
perspectives
September 23rd, 2025
The Chief Medical Officer–Statistician Partnership: How Alignment Builds Investor Confidence
perspectives
September 16th, 2025
Design To De-Risk, The Fastest Way To Earn Investor Trust
perspectives
September 9th, 2025
Advancement of Personalized Treatment Strategies in Oncology Companion Diagnostics and Biomarkers